Resolvyx Pharmaceuticals

... the end in inflammation

Press Releases

11.02.09 - 

Resolvyx Scientific Founder Publishes Breakthrough Study Demonstrating Resolvins Potently Inhibit Inflammation and Suppress Microbial Load in Sepsis Model

09.18.09 - 

Resolvyx Granted U.S. Patent for the First Resolvin Therapeutic to Enter Human Trials

08.24.09 - 

Resolvyx Announces Positive Data from Phase 2 Clinical Trial of the Resolvin RX-10045 in Patients with Dry Eye Syndrome

07.20.09 - 

Resolvyx Announces Management Transition Plan

06.23.09 - 

Resolvyx Initiates Phase I Clinical Trial of Novel Resolvin, RX-10001, for Asthma and Inflammatory Diseases

05.05.09 - 

Resolvyx Presents Data Demonstrating Potential for Resolvin Therapeutics to Treat Corneal and Retinal Eye Diseases at ARVO 2009 Meeting

04.27.09 - 

Resolvyx to Present Data on Novel Resolvin Drug Candidates for Eye Disease at ARVO Annual Meeting

04.15.09 - 

Resolvyx Appoints Industry Leader Philip Vickers as Chief Scientific Officer

12.18.08 - 

Resolvyx Announces Initiation of PhaseI/II Clinical trial of Novel Resolvin Therapeutic RX-10045 in Patients with Dry Eye

11.20.08 - 

Resolvyx Announces Open IND for RX-10045, the Lead Resolvin Therapeutic for Dry Eye

11.20.08 - 

National Neurovision Research Institute (NNRI) and Resolvyx Pharmaceuticals Collaborate to Assess Resolvins to Treat Degenerative Eye Diseases

07.03.08 - 

Resolvyx Scientific Advisors Publish First In-Vivo Data Showing Resolvins Suppress IL-23 and IL-17, Key Mediators of Inflammatory Disease

06.24.08 - 

FierceBiotech Names Resolvyx Pharmaceuticals as One of the "Fierce 15" Biotech Companies of 2008

05.01.08 - 

Resolvyx Compounds Show Promise In Treatment of Ocular Disease

04.24.08 - 

Resolvyx to Present Data on Novel Resolvin Drug Candidates for Eye Disease at ARVO Annual Meeting

04.22.08 - 

Resolvyx Pharmaceuticals Strengthens Its Board of Directors with Industry Leaders

04.22.08 - 

Resolvyx Pharmaceuticals Raises $25 Million in Series B Financing

04.01.08 - 

Resolvyx Pharmaceuticals Presents Data for Novel Resolvin Therapeutic at ACC

09.10.07 - 

Resolvyx Pharmaceuticals Hires James Nichols as EVP of Corporate Development

12.09.05 - 

Resolvyx Pharmaceuticals wins $17M in first-round funding

Resolvins modify function of several pathways in a "many-to-one" approach with a high potential for efficacy across different etiologies and pathologies